This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Zimmermann, S. Articles by Göttlicher, M. Search for Related Content PubMed PubMed Citation Articles by Zimmermann, S. Articles by Göttlicher, M.

Reduced Body Size and Decreased Intestinal Tumor Rates in HDAC2-Mutant Mice

Institutes of ¹ Toxicology and ² Developmental Genetics, GSF National Research Center for Environment and Health, Neuherberg, Germany; ³ Department of Biomolecular Sciences and Biotechnologies, University of Milan; ⁴ Department of Experimental Oncology, European Institute of Oncology, Milan, Italy; and ⁵ Institute of Toxicology and Environmental Hygiene, Technical University Munich, Munich, Germany

Requests for reprints: Martin Göttlicher, Institute of Toxicology, GSF National Research Center for Environment and Health, Ingolstädter Landstraße 1, Neuherberg D-85764, Germany. Phone: 49-89-3187-2446; Fax: 49-89-3187-2494; E-mail: martin.goettlicher{at}gsf.de.

Histone deacetylases (HDAC) reverse the acetylation of histone and nonhistone proteins and thereby modulate chromatin structure and function of nonhistone proteins. Many tumor cell lines and experimental tumors respond to HDAC inhibition. To assess the role of an individual HDAC isoenzyme in physiology and tumor development, HDAC2-mutant mice were generated from a gene trap embryonic stem cell clone. These mice express a catalytically inactive fusion protein of the NH₂-terminal part of HDAC2 and ß-galactosidase, which fails to integrate into corepressor complexes with mSin3B. They are the first class 1 HDAC mutant mice that are viable although they are 25% smaller than their littermates. Cell number and thickness of intestinal mucosa are reduced. Mutant embryonic fibroblasts fail to respond to insulin-like growth factor I (IGF) by the IGF-I–induced increase in cell number observed in wild-type cells. These data suggest a novel link between HDACs and IGF-I–dependent responses. Crossing of HDAC2-mutant with tumor-prone APC^min mice revealed tumor rates that are lower in HDAC2-deficient mice by 10% to 100% depending on segment of the gut and sex of the mice. These mice provide evidence that the key functions of HDAC2, although not essential for survival of the organism, play a rate-limiting role for tumor development in vivo. [Cancer Res 2007;67(19):9047–54]